Revolution Medicines director Elizabeth M. Anderson disposes of $1,949,321.86 in common shares
Bitget2026/09/24 22:00- Elizabeth M. Anderson, director, cut her direct stake in Revolution Medicines common stock to 4,333 shares on Sep. 22, 2026.
- The change followed option exercise of 5,070 shares at USD 1.12, then sales totaling 10,143 shares at USD 191.8521-USD 195.15.
- Derivative holdings fell to 1,095 stock options exercisable at USD 1.12, expiring Apr. 19, 2028.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank Group’s credit risk rises to a four-year high, as AI bets and acquisition rumors heighten leverage concerns
Due to increased market concerns over AI-related financing and potential large-scale acquisitions, SoftBank Group's credit risk indicator—the credit default swap (CDS)—has risen to its highest level in nearly four years.
Microsoft (MSFT.US) faces a "higher bar" after its rebound! Morgan Stanley remains bullish: Azure growth and Copilot commercialization are key drivers, target price set at $600
Morgan Stanley stated that Microsoft's stock price has recently rebounded, so the tech giant will face a "higher hurdle" if it wants to maintain its upward momentum.
Report: OpenAI plans to accelerate fundraising before Anthropic goes public
OpenAI is racing against time—in order to secure funding ahead of rival Anthropic’s IPO, the company has significantly compressed its fundraising timeline, aiming to complete approximately $30 billion in private financing, which could push its valuation past $1.4 trillion upon completion. Major investors such as SoftBank and MGX are already engaged in discussions. Both AI giants are targeting trillion-dollar valuations, and their largely overlapping investor bases are being forced to make simultaneous bets on both ventures within just a few days.
Crypto prices
More
